Article
Medicine, General & Internal
Shuguang Zuo, Min Wei, Bohao He, Anxian Chen, Shiqun Wang, Lingkai Kong, Yenan Zhang, Gang Meng, Tiancheng Xu, Jingyi Wu, Fuming Yang, Hailin Zhang, Shibing Wang, Ciliang Guo, Junhua Wu, Jie Dong, Jiwu Wei
Summary: The study demonstrates that VV-alpha-TIGIT exhibits effective anti-tumor efficacy in various tumor models, particularly achieving approximately 70% complete tumor regression in an ascites tumor model. Treatment with VV-alpha-TIGIT also significantly increases the recruitment and activation of T cells in TME.
Review
Immunology
Lalitha Palanivelu, Ching-Hsuan Liu, Liang-Tzung Lin
Summary: Cancer is a major global health concern, causing millions of deaths each year. Traditional chemotherapy has limitations such as drug resistance and off-target effects, and cancer cells often develop ways to evade immune surveillance. However, oncolytic viro-immunotherapy can trigger immunogenic cell death (ICD), leading to an antitumor immune response. Oncolytic viruses can infect and destroy targeted cancer cells, stimulate the immune system, and release neoantigens to enhance antitumor immunity. This review discusses the concept of ICD in cancer and strategies to enhance the immunogenicity of oncolytic viruses.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Alvaro Morales-Molina, Stefano Gambera, Angela Leo, Javier Garcia-Castro
Summary: The study demonstrates that oncolytic virotherapy can significantly reduce tumor growth of osteosarcoma, particularly when combined with granulocyte-colony stimulating factor (G-CSF) to increase immune infiltration into the tumors and reduce T cell exhaustion.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Chemistry, Multidisciplinary
Yachao Li, Lian Li, Jiawei Wang, D. Christopher Radford, Zhongwei Gu, Jindrich Kopecek, Jiyuan Yang
Summary: Dendronized polymer enhances the efficacy of oncolytic peptides for immunotherapy by inducing immunogenic cell death in cancer cells, converting immunosuppressive tumors to immunoresponsive ones, and increasing the number of cytotoxic T cells. Combination with immune checkpoint blockade further enhances efficacy and results in complete tumor eradication in mice, indicating a promising platform for oncolytic immunotherapy.
JOURNAL OF CONTROLLED RELEASE
(2021)
Article
Biochemistry & Molecular Biology
Philipp Kalus, Jolien De Munck, Sarah Vanbellingen, Laura Carreer, Thessa Laeremans, Katrijn Broos, Ines Dufait, Julia K. Schwarze, Ivan Van Riet, Bart Neyns, Karine Breckpot, Joeri L. Aerts
Summary: The immune system plays a crucial role in the specific killing of tumor cells by oncolytic viruses (OVs). OVs can trigger anti-tumor immune responses by delivering innate signals and inducing immunogenic cell death (ICD). This study shows that Talimogene laherparepvec (T-VEC), a type 1 herpes simplex virus-based OV, has the capacity to induce ICD and promote the maturation of myeloid dendritic cells. These findings solidify the importance of OVs in cancer immunotherapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Immunology
Cao-Sang Truong, So Young Yoo
Summary: Therapeutic cancer vaccines induce long-term immune response by targeting tumor-associated antigens, reducing adverse effects. Vaccinia virus (VV) as an oncolytic virus has promising potential in lung cancer treatment. Non-small cell lung cancer is highly responsive to immunotherapy.
Review
Oncology
Amirhossein Mardi, Anastasia Shirokova, Rebar N. Mohammed, Ali Keshavarz, Angelina O. Zekiy, Lakshmi Thangavelu, Talar Ahmad Merza Mohamad, Faroogh Marofi, Navid Shomali, Amir Zamani, Morteza Akbari
Summary: CAR T-cell therapy has shown progress in hematologic malignancies but faces challenges in solid tumors. Combining oncolytic virotherapy with CAR T-cells may be a promising strategy to overcome these obstacles.
CANCER CELL INTERNATIONAL
(2022)
Article
Oncology
Wenfeng Liu, Yang Liu, Cheng Hu, Cuiying Xu, Jiehong Chen, Yinting Chen, Jing Cai, Guangmei Yan, Wenbo Zhu
Summary: Oncolytic virotherapy can increase the number of Treg cells in the tumor microenvironment, while targeting Treg cells can enhance the anti-tumor effect of M1-based oncolytic virotherapy.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Review
Oncology
Terry R. Medler, Tiffany C. Blair, Marka R. Crittenden, Michael J. Gough
Summary: This review discusses the variations in the definition of tumor immunogenicity and the differences between tumor models, and then explores how these principles apply to the response to radiation therapy. By identifying radioimmunogenic tumor models that are particularly responsive to immunotherapy when combined with radiation, interventions can be identified to convert unresponsive tumors to also respond to these treatments.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Weilin Liu, Hongqi Chen, Zhi Zhu, Zuqiang Liu, Congrong Ma, Yong J. Lee, David L. Bartlett, Zong-Sheng Guo
Summary: The study found that the combination of the ferroptosis activator Erastin with the oncolytic vaccinia virus could effectively inhibit tumor growth, prolong host survival, and enhance antitumoral immunity in hepatocellular carcinoma and colon cancer models.
Article
Oncology
Alexander Muik, Homer C. Adams, Friederike Gieseke, Isil Altintas, Kristina B. Schoedel, Jordan M. Blum, Bianca Sanger, Saskia M. Burm, Eliana Stanganello, Dennis Verzijl, Vanessa M. Spires, Fulvia Vascotto, Aras Toker, Juliane Quinkhardt, Mark Fereshteh, Mustafa Diken, David P. E. Satijn, Sebastian Kreiter, Tahamtan Ahmadi, Esther C. W. Breij, Ozlem Tureci, Kate Sasser, Ugur Sahin, Maria Jure-Kunkel
Summary: DuoBody-CD40x4-1BB is a novel antibody capable of enhancing antitumor immunity by modulating the functions of immune cells. In vitro and in vivo experiments have demonstrated its ability to enhance dendritic cell and T-cell functions, as well as its biological activity in patients with advanced solid tumors. These findings suggest that targeting CD40 and 4-1BB with an Fc-inert bispecific antibody may be an effective approach for cancer treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Biochemistry & Molecular Biology
Danni Lin, Yinan Shen, Tingbo Liang
Summary: Oncolytic viruses (OVs) have gained attention for their potential in inducing direct tumor cell lysis and cancer immune effects. Recent studies have demonstrated promising clinical outcomes and advances in modifying OVs to enhance their targeting and therapeutic efficacy. Combination therapies with other agents have also shown encouraging antitumor effects.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2023)
Review
Oncology
Johannes P. W. Heidbuechel, Christine E. Engeland
Summary: Bispecific T cell engagers (BiTEs) and oncolytic viruses (OVs) are emerging cancer immunotherapies that redirect T cells to tumor surface antigens and selectively infect malignant cells to mediate tumor vaccination effects, respectively. These two approaches can synergize with each other and with other immunotherapies, such as CAR T cells and immune checkpoint inhibitors, to enhance anti-tumor effects.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Shyambabu Chaurasiya, Yuman Fong, Susanne G. Warner
Summary: Oncolytic viruses are a new class of therapeutics that have shown promise in clinical trials, although their anti-tumor efficacy as monotherapy is modest. Most oncolytic viruses are well tolerated, even in immune-suppressed patients, at the currently defined highest feasible doses. Enhancing the potency of oncolytic viruses is necessary for more viruses to be used effectively in clinical settings, thus they are being studied in combination with other therapies for higher therapeutic benefits.
Review
Immunology
Yi-Ying Wu, Te-Kai Sun, Ming-Shan Chen, Muhammad Munir, Hung-Jen Liu
Summary: Recent reports indicate the significant role of oncolytic viruses (OVs) in cancer therapy. Infection with OVs such as oncolytic vaccinia virus (OVV), vesicular stomatitis virus (VSV), parvovirus, mammalian reovirus (MRV), human adenovirus, Newcastle disease virus (NDV), herpes simplex virus (HSV), avian reovirus (ARV), Orf virus (ORFV), inactivated Sendai virus (ISV), enterovirus, and coxsackievirus provides unique opportunities in immunotherapy through diverse and dynamic pathways. This mini-review focuses on the mechanisms of OVs-mediated virotherapy and their effects on immunogenic cell death (ICD), apoptosis, autophagy, and regulation of the immune system.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2023)
Article
Oncology
Marine Ricordel, Johann Foloppe, Delphine Antoine, Annie Findeli, Juliette Kempf, Pascale Cordier, Aude Gerbaud, Benoit Grellier, Monika Lusky, Eric Quemeneur, Philippe Erbs
Article
Oncology
Markus Moehler, Annett Maderer, Anne Ehrlich, Friedrich Foerster, Arno Schad, Tanja Nickolay, Christian Ruckes, Arndt Weinmann, Visvakanth Sivanathan, Jens U. Marquardt, Peter Robert Galle, Marcus Woerns, Thomas Thomaidis
Article
Oncology
J. W. Holch, I. Ricard, S. Stintzing, L. Fischer von Weikersthal, T. Decker, A. Kiani, U. Vehling-Kaiser, T. Heintges, C. Kahl, F. Kullmann, W. Scheithauer, M. Moehler, I. Jelas, D. P. Modest, C. B. Westphalen, J. C. von Einem, M. Michl, V. Heinemann
EUROPEAN JOURNAL OF CANCER
(2019)
Article
Oncology
Markus Moehler, Min-Hee Ryu, Mikhail Dvorkin, Keun-Wook Lee, Hasan S. Coskun, Rachel Wong, Hyun C. Chung, Artem Poltoratsky, Akihito Tsuji, Chia Jui Yen, Alina S. Muntean, Samuel Le Sourd, Gina M. Vaccaro, Lindsay Overton, Narikazu Boku, Zev A. Wainberg, Manish Patel, Maitreyi Sharma, Huiling Xiong, Ilaria Conti, Julien Taieb, Yung-Jue Bang
Article
Virology
Patricia Kleinpeter, Christelle Remy-Ziller, Eline Winter, Murielle Gantzer, Virginie Nourtier, Juliette Kempf, Julie Hortelano, Doris Schmitt, Huguette Schultz, Michel Geist, Catherine Brua, Chantal Hoffmann, Yasmin Schlesinger, Dominique Villeval, Christine Thioudellet, Philippe Erbs, Johann Foloppe, Nathalie Silvestre, Laetitia Fend, Eric Quemeneur, Jean-Baptiste Marchand
JOURNAL OF VIROLOGY
(2019)
Article
Oncology
Johann Foloppe, Juliette Kempf, Nicolas Futin, Jacqueline Kintz, Pascale Cordier, Christelle Pichon, Annie Findeli, Fabien Vorburger, Eric Quemeneur, Philippe Erbs
MOLECULAR THERAPY-ONCOLYTICS
(2019)
Article
Oncology
Adrian Pelin, Johann Foloppe, Julia Petryk, Ragunath Singaravelu, Marian Hussein, Florian Gossart, Victoria A. Jennings, Lawton J. Stubbert, Madison Foster, Christopher Storbeck, Antonio Postigo, Elena Scut, Brian Laight, Michael Way, Philippe Erbs, Fabrice Le Boeuf, John C. Bell
MOLECULAR THERAPY-ONCOLYTICS
(2019)
Article
Veterinary Sciences
Jeremy Beguin, Virginie Nourtier, Murielle Gantzer, Sandrine Cochin, Johann Foloppe, Jean-Marc Balloul, Eve Laloy, Dominique Tierny, Bernard Klonjkowski, Eric Quemeneur, Christelle Maurey, Philippe Erbs
BMC VETERINARY RESEARCH
(2020)
Article
Oncology
Tiphaine Delaunay, Joelle Nader, Marion Grard, Isabelle Farine, Vera Hedwig, Johann Foloppe, Thibaut Blondy, Mathilde Violland, Daniel Pouliquen, Marc Gregoire, Nicolas Boisgerault, Philippe Erbs, Jean-Francois Fonteneau
MOLECULAR THERAPY-ONCOLYTICS
(2020)
Article
Multidisciplinary Sciences
Jeremy Beguin, Murielle Gantzer, Isabelle Farine, Johann Foloppe, Bernard Klonjkowski, Christelle Maurey, Eric Quemeneur, Philippe Erbs
Summary: The study evaluated the safety, biodistribution, and shedding of TG6002, a recombinant oncolytic vaccinia virus, administered intravenously in immune-competent healthy dogs, showing a good safety profile and supporting its potential for clinical trials in canine cancer patients and further development as human cancer therapy.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Jeremy Beguin, Johann Foloppe, Christelle Maurey, Eve Laloy, Julie Hortelano, Virginie Nourtier, Christelle Pichon, Sandrine Cochin, Pascale Cordier, Helene Huet, Eric Quemeneur, Bernard Klonjkowski, Philippe Erbs
MOLECULAR THERAPY-ONCOLYTICS
(2020)
Article
Biochemistry & Molecular Biology
Franck Gallardo, Doris Schmitt, Renee Brandely, Catherine Brua, Nathalie Silvestre, Annie Findeli, Johann Foloppe, Sokunthea Top, Sandrine Kappler-Gratias, Charlotte Quentin-Froignant, Renaud Morin, Jean-Michel Lagarde, Kerstin Bystricky, Stephane Bertagnoli, Philippe Erbs
Article
Veterinary Sciences
Jeremy Beguin, Matthias Kohlhauer, Eve Laloy, Frederique Degorce, Baptiste Moreau, Eric Quemeneur, Philippe Erbs, Bernard Klonjkowski, Christelle Maurey
Summary: Long-term administration of 5-fluorocytosine in healthy dogs resulted in cutaneous toxicity, indicating that pharmacotherapy should be adjusted to reduce toxicity in targeted chemotherapy.
BMC VETERINARY RESEARCH
(2021)
Article
Biophysics
Arianna Mencattini, Christine Lansche, Irina Veith, Philippe Erbs, Jean-Marc Balloul, Eric Quemeneur, Stephanie Descroix, Fatima Mechta-Grigoriou, Gerard Zalcman, Cecile Zaupa, Maria Carla Parrini, Eugenio Martinelli
Summary: Organ-on-chip and tumor-on-chip microfluidic cell cultures are important for modeling organ functions, diseases, drug development, and personalized medicine. Analyzing the large amount of bio-images acquired in these 3D microenvironments is a challenge, which can be addressed by the interdisciplinary contributions of computer science and electronic engineering. In this study, we applied this approach to study the oncolytic vaccinia virus (OVV) in cancer immunotherapy, and found a synergistic cooperation between OVV and immune cells in killing cancer cells. We also observed changes in immune cell kinetics and a correlation between cancer cell infection and cancer-immune interaction time.
BIOSENSORS & BIOELECTRONICS
(2022)
Article
Immunology
Rodrigo Nalio Ramos, Caroline Tosch, Fiorella Kotsias, Marie-Christine Claudepierre, Doris Schmitt, Christelle Remy-Ziller, Chantal Hoffmann, Marine Ricordel, Virginie Nourtier, Isabelle Farine, Laurence Laruelle, Julie Hortelano, Clementine Spring-Giusti, Christine Sedlik, Christophe Le Tourneau, Caroline Hoffmann, Nathalie Silvestre, Philippe Erbs, Kaidre Bendjama, Christine Thioudellet, Eric Quemeneur, Eliane Piaggio, Karola Rittner
Summary: This study identifies bovine pseudocowpox virus (PCPV) as a viral vector with strong immune stimulating abilities, capable of activating immune cells and reversing tumor-induced T-cell suppression. Using PCPV encoding the HPV16 E7 protein as a vaccine, significant antigen-specific T-cell responses were induced in experimental tumor-bearing mice, resulting in complete tumor regression. From a translational perspective, PCPV-E7 effectively stimulated IFN-γ production by T cells from tumor-draining lymph nodes of HPV+-infected cancer patients.
CLINICAL & TRANSLATIONAL IMMUNOLOGY
(2022)